What is Entia Biosciences Inc?
engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States.
ERGO · Verdict
Moderate reward · elevated risk
ERGO's standout is balance sheet; volatility and profitability weigh on the picture.
Based on 63% data coverage
ERGO · Verdict
Top decile vs peers
Weak vs peers
0% return on equity
Model-based scoring. For information only — not financial advice.
engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 10.10K.
The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.